CompletedNCT05227118

Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Medication studyAges 65–85United StatesSchizophrenia

The study in practice

Understand this study

Listed age limits: 65 years to 85 years.

Listed locations: Santa Ana, United States · Cutler Bay, United States and 6 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: July 1, 2022

Recruitment status: Completed
Enrollment listed in the registry: 29
Sponsor: Merck Sharp & Dohme LLC
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 65 Years to 85 Years
Official registry ID: NCT05227118
Official title: Show the full official title
A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK-8189 in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis

Completed

Santa Ana · Cutler Bay · Hallandale

5 more locations

FAQ

Who is behind this study?

The study sponsor is Merck Sharp & Dohme LLC.

Did this study involve medication?

Yes. The study involved medication, including Elpipodect and Placebo.

Who was this study for?

Listed age limits: 65 years to 85 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.